High-risk women benefitfrom mammography, MRI
Alternating two screening modalities pays off forwomen with high genetic likelihood of breast cancerAlternating MRI with mammographyevery six months picks up breastcancers missed when mammographyis performed alone for high-riskwomen.
Alternating two screening modalities pays off for women with high genetic likelihood of breast cancer Alternating MRI with mammography every six months picks up breast cancers missed when mammography is performed alone for high-risk women.
The two screening modalities are alternated in many special programs for women with confirmed BRCA1 and BRCA2 genetic mutations giving them an exceptionally high risk for developing breast cancer. Until now, no one has established a scientific basis for adopting the tactic.
Dr. Huong Le-Petross, an assistant professor of radiology at M.D. Anderson Cancer Center in Houston, reviewed the medical records of 334 consecutive women. Of those patients, 26% (86) underwent annual screening mammography and MRI, alternating every six months. The rest underwent prophylactic mastectomies or were treated with chemoprevention.
Overall, the researchers identified nine cancers in seven women with screening MRI: six invasive ductal, one invasive lobular, and two ductal carcinomas in situ.
Four of these cancers were identified only with MRI, four were identified with both MRI and mammography, and one was missed by both modalities before diagnosis after prophylactic mastectomy.
“The global picture is that MRI can pick up cancers that mammography cannot,” Le-Petross said.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
